首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1419132

院內感染治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按藥物類別、感染類型、配銷通路和地理位置

Hospital Acquired Infection Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Class, Infection Type, Distribution Channel, and Geography

出版日期: 2023年12月11日 | 出版商:

The Insight Partners | 英文 171 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

全球院內感染治療市場預計將從2022年的150.99億美元增至2030年的199.78億美元。預計2022年至2030年該市場將以3.6%的CAGR成長。

推動市場成長的關鍵因素包括院內感染（HAI）的高盛行率以及對病人安全和優質照護的日益關注。然而，抗菌素抗藥性的威脅阻礙了市場的成長。

院內感染治療市場的市場促進因素

中心靜脈導管相關的血流感染、導管相關的泌尿道感染和呼吸器相關的肺炎是醫療保健相關感染 (HAI) 的幾個例子。這些感染也可能發生在手術部位。根據美國疾病管制與預防中心（CDC）2021年發布的《2020年國家和州醫療保健相關感染進展報告》，中心靜脈導管相關血流感染、耐甲氧西林金黃色葡萄球菌（MRSA）菌血症和呼吸器病例2019 年至 2020 年間，美國相關事件分別增加了 24%、35% 和 15%。

此外，根據國家醫療安全網路 (NHSN) 2022 年 1 月的報告，泌尿道感染 (UTI) 是第五大常見的醫療保健相關感染類型。泌尿道感染佔急診醫院病情的 9.5% 以上。導管相關性泌尿道感染 (CAUTI) 是由用於從膀胱排出尿液的導尿管引起的。 CAUTI 是住院 UTI 患者中最常見的感染之一。根據美國疾病管制與預防中心 (CDC) 的數據，近 75% 的感染與導尿管有關。住院期間，15%至25%的住院患者必須使用導尿管。長期使用導尿管是患有 CAUTI 最主要的危險因子。 CAUTI 併發症會導致患者痛苦、住院時間延長、治療費用增加，甚至死亡。

院內感染治療市場的機遇

新型抗菌藥物（包括抗生素、抗真菌藥物和抗病毒藥物）的持續開發，為對抗 HAI、解決新出現的抗藥性模式和擴大治療方案提供了機會。此外，醫療機構、製藥公司和研究組織之間的合作措施為發現新的治療標靶、發現抗生素和開發下一代感染治療策略提供了機會。

院內感染治療市場：細分概述

醫院感染治療市場依藥品類別分為抗菌、抗病毒、抗真菌等。抗菌藥物領域在 2022 年佔據最大的市場佔有率，預計 2022-2030 年CAGR最高。

本院獲得性感染治療市場依感染類型分為泌尿道感染、呼吸器相關性肺炎、手術部位感染、血流感染等院內感染。泌尿道感染細分市場在 2022 年佔據最大的市場佔有率。然而，預計 2022 年至 2030 年呼吸器相關肺炎細分市場的CAGR最高。

醫院感染治療市場依配銷通路分為醫院藥局、零售藥局、電子商務等。 2022年，醫院藥局細分市場佔據最大的市場佔有率，預計該細分市場在2022-2030年期間複合CAGR最高。

院內感染治療市場：地理概況

據估計，2022年至2030年，亞太地區的CAGR最高。印度和中國等亞太國家的院內感染治療市場成長潛力巨大。該地區的發展中國家改善了醫療基礎設施，增加了醫療支出，並越來越注重採用先進的醫療技術，為市場擴張提供了機會。

2022年，北美在全球院內感染治療市場中佔據最大佔有率。美國醫院感染發生率很高，這推動了院內感染治療市場的成長。根據 CDC 的數據，在任何一天，大約每 31 名醫院患者中就有 1 名至少患有一次 HAI。同樣，根據疾病預防和健康促進辦公室的數據，醫院感染和其他感染可導致敗血症，在美國每年導致 170 萬例病例和 27 萬人死亡。因此，美國人醫院感染的高盛行率推動了院內感染治療市場的成長。

此外，根據美國醫療保險和醫療補助服務中心的數據，2021年美國國家醫療保健支出將增加2.7%，達到4.3兆美元，即人均12,914美元。此外，醫療支出佔國內生產毛額的18.3%。此外，根據美國衛生與公眾服務部的數據，2019年至2028年，國家衛生支出預計將以每年平均5.4%的速度成長，到2028年預計將達到6.2兆美元。增加醫院感染藥物開發相關研究的各種資金來源，刺激院內感染治療的需求。

在準備院內感染治療市場報告時提到的一些主要一手和二手來源包括世界銀行數據、國家衛生服務體系 (NHS)、FDA（食品和藥物管理局）、EMA（歐洲藥品管理局）和WHO （世界衛生組織）。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 11 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 12 章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 13 章：院內感染治療市場 - 主要公司概況

Merck and Co. Inc.

注意 - 將為以下公司列表提供類似資訊

輝瑞公司
艾伯維公司
帕拉泰克製藥公司
尤吉亞美國有限責任公司
雅培實驗室
坎伯蘭製藥公司
Innoviva 專業治療公司
西普拉有限公司
禮來公司

第 14 章：附錄

詞彙表
關於 Insight Partners
市場情報雲

簡介目錄

Product Code: TIPRE00029976

The global hospital-acquired infection treatment market is expected to reach US$ 19.978 billion in 2030 from US$ 15.099 billion in 2022. The market is estimated to grow with a CAGR of 3.6% from 2022 to 2030.

The key factors driving the market's growth include the high prevalence of hospital-acquired infections (HAI) and the growing focus on patient safety and quality care. However, the threat of antimicrobial resistance hinders market growth.

Market Drivers of the Hospital-Acquired Infection Treatment Market

Central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia are a few examples of healthcare-associated infections (HAIs). These infections can also arise at surgical sites. According to the Centers for Disease Control and Prevention (CDC) report "2020 National and State Healthcare-Associated Infections Progress Report" published in 2021, cases of central line-associated bloodstream infections, Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and ventilator-associated events increased by 24%, 35%, and 15%, respectively, in the US between 2019 and 2020.

Furthermore, According to the January 2022 report from the National Healthcare Safety Network (NHSN), urinary tract infections (UTIs) are the fifth most common type of healthcare-associated infection. UTIs account for more than 9.5% of acute care hospital conditions. Catheter-associated urinary Tract Infection (CAUTI) is caused by urinary catheters used to drain urine from the bladder. CAUTI is one of the most frequent infections among hospitalized UTI patients. According to the Centers for Disease Control and Prevention (CDC), nearly 75% of infections are related to a urinary catheter. During hospital stays, 15% to 25% of hospitalized patients must use urinary catheters. Prolonged urinary catheter use is the most major risk factor for getting CAUTI. CAUTI complications entail patient suffering, prolonged hospital stays, increased treatment costs, and even death.

Opportunities in the Hospital-Acquired Infection Treatment Market

The continuous development of novel antimicrobial agents, including antibiotics, antifungals, and antivirals, presents opportunities for combating HAIs, addressing emerging resistance patterns, and expanding the armamentarium of treatment options. Additionally, collaborative initiatives among healthcare institutions, pharmaceutical companies, and research organizations present opportunities for discovering novel therapeutic targets, discovering antibiotics, and developing next-generation infection treatment strategies.

Hospital Acquired Infection Treatment Market: Segmental Overview

The hospital acquired infection treatment market, by drug class, is segmented into antibacterial, antiviral, antifungal, and others. The antibacterial drugs segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022-2030.

The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held the largest market share in 2022. However, the ventilator-associated pneumonia segment is anticipated to register the highest CAGR from 2022 to 2030.

The hospital acquired infection treatment market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. In 2022, the hospital pharmacies segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022-2030.

Hospital Acquired Infection Treatment Market: Geographical Overview

Asia Pacific is estimated to register the highest CAGR from 2022 to 2030. Countries in the Asia Pacific, such as India and China, hold significant potential for the hospital-acquired infection treatment market growth. Developing countries in the region with improving healthcare infrastructure, increasing healthcare expenditure, and a rising focus on adopting advanced medical technologies offer opportunities for market expansion.

In 2022, North America held the largest share of the global hospital-acquired infection treatment market. The US has a high prevalence of HAI, which propels the hospital-acquired infection treatment market growth. As per the CDC, on any given day, about 1 in 31 hospital patients has at least one HAI. Similarly, according to the Office of Disease Prevention and Health Promotion, HAIs and other infections can lead to sepsis, and it causes 1.7 million illness cases and 270,000 deaths per year in the US. Thus, the high prevalence of HAI among people in the US fuels the hospital-acquired infection treatment market growth.

Furthermore, according to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US will increase by 2.7 percent in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Also, health spending accounted for 18.3 percent of the nation's Gross Domestic Product. Furthermore, according to the US Department of Health & Human Services, National health spending is expected to grow at a 5.4% annual rate from 2019 to 2028, and it is expected to reach US$ 6.2 trillion by 2028. The rising health expenditure is estimated to increase various funding sources in the research related to the development of HAI drugs, fueling the demand for hospital-acquired infection treatment.

A few of the major primary and secondary sources referred to while preparing the report on the hospital-acquired infection treatment market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Hospital Acquired Infection Treatment Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Hospital Acquired Infection Treatment Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Hospital Acquired Infection Treatment Market - Global Market Analysis

6.1 Hospital Acquired Infection Treatment - Global Market Overview
6.2 Hospital Acquired Infection Treatment - Global Market and Forecast to 2030

7. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million) - By Drug Class, 2020-2030

7.1 Overview
7.2 Antibacterial Drugs
7.3 Antiviral Drugs
7.4 Antifungal Drugs
7.5 Others

8. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million) - By Infection Type, 2020-2030

8.1 Overview
8.2 Urinary Tract Infections
8.3 Ventilator-associated Pneumonia
8.4 Surgical Site Infections
8.5 Bloodstream Infections
8.6 Other Hospital Infections

9. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

9.1 Overview
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 E-Commerce
9.5 Others

10. Hospital Acquired Infection Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

10.1 North America
- 10.1.1 North America Hospital Acquired Infection Treatment Market Overview
- 10.1.2 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts to 2030
- 10.1.3 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Drug Class
- 10.1.4 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Infection Type
- 10.1.5 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
- 10.1.6 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Hospital Acquired Infection Treatment Market
    - 10.1.6.1.1 United States Hospital Acquired Infection Treatment Market, by Drug Class
    - 10.1.6.1.2 United States Hospital Acquired Infection Treatment Market, by Infection Type
    - 10.1.6.1.3 United States Hospital Acquired Infection Treatment Market, by Distribution Channel
  - 10.1.6.2 Canada Hospital Acquired Infection Treatment Market
    - 10.1.6.2.1 Canada Hospital Acquired Infection Treatment Market, by Drug Class
    - 10.1.6.2.2 Canada Hospital Acquired Infection Treatment Market, by Infection Type
    - 10.1.6.2.3 Canada Hospital Acquired Infection Treatment Market, by Distribution Channel
  - 10.1.6.3 Mexico Hospital Acquired Infection Treatment Market
    - 10.1.6.3.1 Mexico Hospital Acquired Infection Treatment Market, by Drug Class
    - 10.1.6.3.2 Mexico Hospital Acquired Infection Treatment Market, by Infection Type
    - 10.1.6.3.3 Mexico Hospital Acquired Infection Treatment Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Hospital Acquired Infection Treatment Market - Key Company Profiles

13.1 Merck and Co. Inc.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies